Academic Journal
Role of Advanced Glycation End Products as New Biomarkers in Systemic Lupus Erythematosus
| العنوان: | Role of Advanced Glycation End Products as New Biomarkers in Systemic Lupus Erythematosus |
|---|---|
| المؤلفون: | Carrión-Barberà, Irene, Triginer, Laura, Tío, Laura, Pérez-García, Carolina, Ribes, Anna, Abad, Victoria, Pros, Ana, Bermúdez López, Marcelino, Castro-Boqué, Eva, Lecube Torelló, Albert, Valdivielso Revilla, José Manuel, Monfort, Jordi, Salman-Monte, Tarek Carlos |
| بيانات النشر: | MDPI |
| سنة النشر: | 2024 |
| المجموعة: | Universitat de Lleida: Repositori Obert UdL |
| مصطلحات موضوعية: | Systemic lupus erythematosus, Advanced glycation end products, Cardiovascular disease, Biomarkers |
| الوصف: | Advanced glycation end-products (AGEs) may play a relevant role as inducers in the chronic inflammatory pathway present in immune-mediated diseases, such as systemic lupus erythematosus (SLE). AGEs concentrations have been associated, with discrepant results to date, with some parameters such as disease activity or accrual damage, suggesting their potential usefulness as biomarkers of the disease. Our objectives are to confirm differences in AGEs levels measured by cutaneous autofluorescence between SLE patients and healthy controls (HC) and to study their correlation with various disease parameters. Cross-sectional study, where AGEs levels were measured by skin autofluorescence, and SLE patients' data were compared with those of sex- and age-matched HC in a 1:3 proportion through a multiple linear regression model. Associations of AGEs levels with demographic and clinical data were analyzed through ANOVA tests. Both analyses were adjusted for confounders. AGEs levels in SLE patients were significantly higher than in HC (p < 0.001). We found statistically significant positive associations with SLE disease activity index (SLEDAI) and damage index (SDI), physician and patient global assessment, C-reactive protein, leukocyturia, complement C4, IL-6 and oral ulcers. We also found a negative statistically significant association with current positivity of anti-nuclear and anti-Ro60 antibodies. AGEs seem to have a contribution in LES pathophysiology, being associated with activity and damage and having a role as a new management and prognosis biomarker in this disease. The association with specific antibodies and disease manifestations may indicate a specific clinical phenotype related to higher or lower AGEs levels. ; This work was supported by the Instituto de Salud Carlos III (ISCIII) and the European Union (Grants number PI18/00059, PI23/00185, RETIC RD16/0009/0011), as well as by the Fundación Española de Reumatología through the Ayuda a la Intensificación de la Actividad Investigadora awarded in 2021, the ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1661-6596 1422-0067 |
| Relation: | Reproducció del document publicat a: https://doi.org/10.3390/ijms25053022; International Journal of Molecular Sciences, 2024, vol. 25, núm. 5; https://doi.org/10.3390/ijms25053022; https://repositori.udl.cat/handle/10459.1/465739 |
| DOI: | 10.3390/ijms25053022 |
| الاتاحة: | https://doi.org/10.3390/ijms25053022 https://repositori.udl.cat/handle/10459.1/465739 |
| Rights: | cc-by (c) authors, 2024 ; Attribution 4.0 International ; info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.46967FA0 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 16616596 14220067 |
|---|---|
| DOI: | 10.3390/ijms25053022 |